Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies involved in the internet-based first consultation pilot in Beijing. Core Insights - The pilot program for internet-based first consultations in Beijing is expected to have landmark significance for nationwide policy expansion, aiming to relieve offline clinical pressure and extend quality medical resources digitally across China [2][6]. - The policy is anticipated to drive online traffic growth and accelerate prescription outflow, particularly in specialties suitable for remote diagnosis such as dermatology, mental health, and nutrition [7][8]. - The integration of "consultation-examination-diagnosis-medication" services is facilitated by this policy, potentially streamlining patient journeys and reducing transportation costs [8]. Summary by Sections Event - On January 31, 2026, the National Health Commission approved a pilot for internet-based first consultations in pediatric specialties in Beijing, running from January to December 2026 [1][5]. Commentary - The pilot aims to address the medical needs of out-of-town patients and relieve non-capital functions in Beijing, with the potential to serve as a reference for similar initiatives nationwide [2][6]. - If the scope of internet-based first consultations expands, it could lead to significant growth in online consultations and related health product sales [7]. - Leading companies like Alibaba Health and JD Health are expected to benefit from the expansion of this policy [8].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the Hong Kong healthcare market experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Highlights - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing an 89% year-on-year increase, and reported a turnaround to profitability [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow and improve access to healthcare services [13].